Key result
Everolimus-eluting PCI proves noninferior to CABG for death, stroke, or MI in left main disease.
Why the study?
Does PCI with everolimus-eluting stents improve the composite end point of death, stroke, or myocardial infarction at 3 years in patients with left main coronary artery disease and low or intermediate SYNTAX scores compared to CABG?
Does PCI with everolimus-eluting stents improve the composite end point of death, stroke, or myocardial infarction at 3 years in patients with left main coronary artery disease and low or intermediate SYNTAX scores compared to CABG?
In patients with left main coronary artery disease and low or intermediate SYNTAX scores, PCI with everolimus-eluting stents is noninferior to CABG for the composite outcome of death, stroke, or MI at 3 years.
Supports PCI with everolimus-eluting stents as an option in selected left main disease; leaves open longer-term durability.
In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years. (Funded by Abbott Vascular; EXCEL ClinicalTrials.gov number, NCT01205776 .).
No takes yet. Share an insight, caveat, or question.
Stone et al. (2016) studied this question. PCI with everolimus-eluting stents was noninferior to CABG for death, stroke, or myocardial infarction at 3 years in patients with left main coronary disease.